This GAG–lipoprotein axis represents a previously unrecognized extracellular mechanism for acquiring ferroptosis protection, distinct from intracellular systems such as GPX4 or FSP1, and may provide therapeutic opportunities for targeting ferroptosis-resistant cancers. Here, GPX4 is linked to cancer.